Quantcast

New Study Demonstrates the Effect of Sensoril® on Cognitive and Psychomotor Performance in Healthy Subjects

January 24, 2014

Natreon, Inc, and NutraGenesis, LLC are pleased to announce a new study published on Sensoril® demonstrates Sensoril’s ability to significantly improve cognitive and psychomotor performance.

Brattleboro, VT (PRWEB) January 24, 2014

Natreon, Inc, and NutraGenesis, LLC are pleased to announce publication of a new study on Sensoril® which demonstrated Sensoril’s ability to significantly improve cognitive and psychomotor performance during simple reaction, choice discrimination, digit symbol substitution, digit vigilance and card sorting tests (when compared with placebo). These particular tests are widely used in clinical studies due to their sensitivity and validity for detecting changes in psychomotor performance in healthy subjects. These results further substantiate the adaptogenic, multi-functional benefits of Sensoril® to optimize cognitive and psychomotor performance by reducing stress.

During this double-blind, placebo-controlled, crossover human clinical trial, 20 healthy male subjects received two, 250 mg capsules daily of Sensoril® or a matching placebo for 14 days. Cognitive and psychomotor performance were assessed pre-dose (day 1) and at 3 hours post-dose on day 15 using the above mentioned computerized psychometric tests. The study published in the peer-reviewed Pharmacognosy Research January-March 2014 issue reported that Sensoril® provided significant improvements in performance and was well tolerated. The study was conducted by researchers at the Department of Clinical Pharmacology and Therapeutics at the NIZAMS Institute of Medical Sciences in Hyderabad, India.

“We are delighted with the results of this study and the compelling data which this research has revealed about Sensoril’s ability to enhance cognitive and psychomotor performance,” says Dr. Sanni Raju, CEO and Chairman of the Board of Natreon, Inc. “Our commitment to building the research and intellectual property platform for Sensoril® on behalf of our customers and partners has been and always will be our first priority.”

Suzanne McNeary, President of NutraGenesis, LLC, the exclusive licensee for Sensoril® in North America, added, “the results of this new study further solidify Sensoril’s superiority in the Ashwagandha marketplace. As the most concentrated, multi-patented, truly full-spectrum Ashwagandha extract with over a decade of safe and efficacious use in the industry, it’s the reason that Sensoril® is the number one choice in Ashwagandha extracts of fine dietary supplement brands around the world.”

About Natreon: Natreon is a 15 year old company with headquarters in New Jersey, with a diversified portfolio of scientifically researched and clinically studied Ayurvedic ingredients. Sensoril® is protected by U.S. Patents 6,153,198; 6,713,092 and 7,318,938; European Patent EP1569669 A2; and Canadian Patent 2,508,478. Sensoril® is a trademark of Natreon, Inc.

About NutraGenesis: Located in the Connecticut River Valley area of Southern Vermont, Nutragenesis LLC is a diversified nutraceutical product marketing company dedicated to the development and commercialization of proprietary, scientifically researched, health-promoting ingredients. NutraGenesis is the exclusive North American sales and marketing agent for Sensoril®.

For the original version on PRWeb visit: http://www.prweb.com/releases/sensoril-ashwagandha/new-study/prweb11515920.htm


Source: prweb



comments powered by Disqus